PBR-06 clinical trials
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses PBR-06 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2009 (1)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 5
Brigham and Women's Hospital (3) · Molecular NeuroImaging (1) · Institute for Neurodegenerative Disorders (1)
Studies
Open first, then newest update. How each study uses PBR-06 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related FatigueCompletedPhase 1/2Brigham and Women's HospitalNCT04144257Written as [F-18]PBR06
- Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple SclerosisWithdrawnPhase 1/2Brigham and Women's HospitalNCT03983252Written as [F-18]PBR06
- Establishing 18F-PBR06 PET Imaging as a Viable Pharmacodynamic Endpoint in MSACompletedPhase 1/2Brigham and Women's HospitalNCT03033680Written as [F-18]PBR06
- Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological ConditionsTerminatedPhase 1Institute for Neurodegenerative DisordersNCT01028209Written as [18F] PBR06
- Evaluation of Microglial Activation in ALS With [18F]PBR06 (Peripheral Benzodiazepine Receptor-06) PETCompletedPhase 1Molecular NeuroImagingNCT03876002Written as [18F]PBR06
Given beside what is tested · 3 — PBR-06 is usual care or a partner of the new treatment
- PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric DiseasesRecruitingPhase 1/2Brigham and Women's HospitalNCT02649985Written as [F-18]PBR06
- 9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple SclerosisCompletedPhase 3Brigham and Women's HospitalNCT04510220Written as [F-18]PBR06
- Effect of Verdiperstat on Microglial Activation in Well-characterized MSA PatientsCompletedEarly Phase 1Brigham and Women's HospitalNCT04616456Written as [F-18]PBR06
Codes
What other systems call PBR-06 · ClinicalTrials.gg INT016590
- Wikidata Q27278164pbr-06One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| Wikidata | Q27278164 | pbr-06 | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.